查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肠阻塞治疗市场报告：2030 年趋势、预测与竞争分析
市场调查报告书
商品编码
1356894

肠阻塞治疗市场报告：2030 年趋势、预测与竞争分析

Intestinal Pseudo Obstruction Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

假性肠阻塞治疗的趋势与预测

预计到 2030 年，全球假性肠阻塞治疗市场将达到 214 亿美元，2024 年至 2030 年年复合成长率为 5.1%。这个市场的主要驱动因素是胃肠道疾病的盛行率不断上升、医疗保健提供者和患者的意识不断提高以及特定治疗方法药物创新的进步。全球肠道假性阻塞治疗市场前景广阔，医院/诊所市场和门诊护理中心市场蕴藏商机。

肠阻塞治疗市场洞察

  • Lucintel 预测，在预测期内，药物治疗仍将是最大的细分市场。
  • 医院仍将是最大的部分，因为它们在肠阻塞的治疗中发挥关键作用，特别是在重症病例和併发症的治疗方面。
  • 由于该地区疾病意识的提高、主要参与者的存在以及医疗保健行业的扩张，北美在预测期内可能仍是最大的细分市场。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球假性肠阻塞治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球肠阻塞治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按症状分類的全球肠阻塞治疗市场
    • 急性
    • 慢性的
  • 全球肠阻塞治疗市场（依诊断）
    • 体检
    • 切片检查
    • 验血
    • 排放试验
    • 影像检查
    • 其他的
  • 按治疗方式分類的全球肠阻塞治疗市场
    • 药品
    • 外科手术
    • 饮食
    • 其他的
  • 按最终用途分類的全球假性肠阻塞治疗市场
    • 医院和诊所
    • 门诊治疗中心
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球肠阻塞治疗市场区域分布
  • 北美肠阻塞治疗市场
  • 欧洲肠阻塞治疗市场
  • 亚太地区假性肠阻塞治疗市场
  • 其他区域性肠假性阻塞治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按症状分類的全球肠阻塞治疗市场成长机会
    • 全球肠阻塞治疗市场诊断成长机会
    • 全球肠阻塞治疗市场依治疗方式的成长机会
    • 全球假性肠阻塞治疗市场成长机会（依最终用途）
    • 全球假性肠阻塞治疗市场按地区成长机会
  • 全球假性肠阻塞治疗市场新趋势
  • 战略分析
    • 新产品开发
    • 全球假性肠阻塞治疗市场的产能扩张
    • 全球肠阻塞治疗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Pfizer
  • Cipla
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited
简介目录

Intestinal Pseudo Obstruction Treatment Trends and Forecast

The future of the global intestinal pseudo obstruction treatment market looks promising with opportunities in the hospitals & clinic and ambulatory care center markets. The global intestinal pseudo obstruction treatment market is expected to reach an estimated $21.40 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are increasing prevalence of gastrointestinal cases, rising awareness among healthcare providers and patients, and growing pharmaceutical innovations for specific treatments.

A more than 150-page report is developed to help in your business decisions.

Intestinal Pseudo Obstruction Treatment by Segment

The study includes a forecast for the global intestinal pseudo obstruction treatment by condition, diagnosis, treatment, end use, and region.

Intestinal Pseudo Obstruction Treatment Market by Condition [Shipment Analysis by Value from 2018 to 2030]:

  • Acute
  • Chronic

Intestinal Pseudo Obstruction Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Physical Examination
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests
  • Others

Intestinal Pseudo Obstruction Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery
  • Diet
  • Others

Intestinal Pseudo Obstruction Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Intestinal Pseudo Obstruction Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Intestinal Pseudo Obstruction Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies intestinal pseudo obstruction treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the intestinal pseudo obstruction treatment companies profiled in this report include-

  • Pfizer
  • Cipla
  • Glaxosmithkline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy'S Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited

Intestinal Pseudo Obstruction Treatment Market Insights

  • Lucintel forecasts that medication will remain the largest segment over the forecast period.
  • Hospitals will remain the largest segment due to as hospital playa an important role in the treatment of intestinal pseudo-obstruction, especially in managing severe cases and complications.
  • North America will remain the largest segment over the forecast period due to increasing awareness towards diseases, presence of major players, and expanding healthcare industry in the region.

Features of the Global Intestinal Pseudo Obstruction Treatment Market

  • Market Size Estimates: Intestinal pseudo obstruction teatment market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Intestinal pseudo obstruction teatment market by various segments, such as by condition, diagnosis, treatment, end use and region in terms of($B).
  • Regional Analysis: Intestinal pseudo obstruction teatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different conditions, diagnosis, treatment, end uses, and region.s for the intestinal pseudo obstruction treatment market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the intestinal pseudo obstruction treatment market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the intestinal pseudo obstruction treatment market size?

Answer: The global intestinal pseudo obstruction treatment market is expected to reach an estimated $21.40 billion by 2030.

Q.2. What is the growth forecast for intestinal pseudo obstruction treatment market?

Answer: The global intestinal pseudo obstruction treatment market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the intestinal pseudo obstruction treatment market?

Answer: The major drivers for this market are increasing prevalence of gastrointestinal cases, rising awareness among healthcare providers and patients, and growing pharmaceutical innovations for specific treatments.

Q.4. What are the major segments for intestinal pseudo obstruction treatment market?

Answer: The future of the intestinal pseudo obstruction treatment market looks promising with opportunities in the hospitals & clinic and ambulatory care center markets.

Q.5. Who are the key intestinal pseudo obstruction treatment market companies?

Answer: Some of the key intestinal pseudo obstruction treatment companies are as follows:

  • Pfizer
  • Cipla
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Lupin Limited

Q.6. Which intestinal pseudo obstruction treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the largest segment over the forecast period.

Q.7. In intestinal pseudo obstruction treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to increasing awareness towards diseases, presence of major players, and expanding healthcare industry in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the intestinal pseudo obstruction treatment market by condition (acute and chronic), diagnosis (physical examination, biopsy, blood test, gastric emptying tests, imaging tests, and others), treatment (medication, surgery, diet, and others), end use (hospitals & clinics, ambulatory care centers, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Intestinal Pseudo Obstruction Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Intestinal Pseudo Obstruction Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Intestinal Pseudo Obstruction Treatment Market by Condition
    • 3.3.1: Acute
    • 3.3.2: Chronic
  • 3.4: Global Intestinal Pseudo Obstruction Treatment Market by Diagnosis
    • 3.4.1: Physical Examination
    • 3.4.2: Biopsy
    • 3.4.3: Blood Test
    • 3.4.4: Gastric Emptying Tests
    • 3.4.5: Imaging Tests
    • 3.4.6: Others
  • 3.5: Global Intestinal Pseudo Obstruction Treatment Market by Treatment
    • 3.5.1: Medication
    • 3.5.2: Surgery
    • 3.5.3: Diet
    • 3.5.4: Others
  • 3.6: Global Intestinal Pseudo Obstruction Treatment Market by End Use
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Ambulatory Care Centers
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Intestinal Pseudo Obstruction Treatment Market by Region
  • 4.2: North American Intestinal Pseudo Obstruction Treatment Market
    • 4.2.2: North American Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.3: European Intestinal Pseudo Obstruction Treatment Market
    • 4.3.1: European Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.3.2: European Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.4: APAC Intestinal Pseudo Obstruction Treatment Market
    • 4.4.1: APAC Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.4.2: APAC Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others
  • 4.5: ROW Intestinal Pseudo Obstruction Treatment Market
    • 4.5.1: ROW Intestinal Pseudo Obstruction Treatment Market by Treatment: Medication, Surgery, Diet, and Others
    • 4.5.2: ROW Intestinal Pseudo Obstruction Treatment Market by End Use: Hospitals & Clinics, Ambulatory Care Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Condition
    • 6.1.2: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by End Use
    • 6.1.5: Growth Opportunities for the Global Intestinal Pseudo Obstruction Treatment Market by Region
  • 6.2: Emerging Trends in the Global Intestinal Pseudo Obstruction Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Intestinal Pseudo Obstruction Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Intestinal Pseudo Obstruction Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Cipla
  • 7.3: GlaxoSmithKline
  • 7.4: Teva Pharmaceutical
  • 7.5: Eli Lilly
  • 7.6: Novartis
  • 7.7: Johnson & Johnson
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: F. Hoffmann-La Roche
  • 7.10: Lupin Limited